Skip to content
OpenCapital
Get started

XOMA Corporation XOMA Xaciato — Rights Receivable Cost Recovery Method

Similar metrics at other companies

Innoviva, Inc. logo
INVAXacduro — Revenue
$18.07M+132%
Ligand Pharmaceuticals logo
LGNDAccrued purchases of financial royalty assets
$0—
Ligand Pharmaceuticals logo
LGNDAT220 — Financial Royalty Assets, Allowance
$121K—
Innoviva, Inc. logo
INVAXerava — Percentage Of Royalty Payable On Net Sales
0.6%0.0pp
Protagonist Therapeutics logo
PTGXAccrued revenue share
$53.66M—
KEE
KEELAccounts Receivable, Allowance for Credit Loss, Recovery
$250—

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×—
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:RightsReceivableCostRecoveryMethod.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's xaciato — rights receivable cost recovery method.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's xaciato — rights receivable cost recovery method?
XOMA Corporation (XOMA) reported xaciato — rights receivable cost recovery method of $21.99M in Q1 2026.
How has XOMA Corporation's xaciato — rights receivable cost recovery method changed year-over-year?
XOMA Corporation's xaciato — rights receivable cost recovery method decreased by 0.0% year-over-year, from $22M to $21.99M.
What does xaciato — rights receivable cost recovery method mean?
This metric represents the carrying value of royalty rights associated with the Xaciato product under the cost recovery accounting method. It reflects the unrecovered investment balance in the underlying therapeutic asset before royalty payments are recognized as income. This balance is critical for assessing the remaining capital recovery period for specific royalty acquisitions.